SCHEMBL3074398

SCHEMBL3074398

COCCCn1ncc2ccc(CO)cc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMO O15229 5/20 0.43
HTR2A P28223 4/20 0.43
HTR2C P28335 4/20 0.43
HTR2B P41595 4/20 0.43
MAPK1 P28482 2/20 0.42
REN P00797 2/20 0.42
MCHR1 Q99705 1/20 0.39
HTR1A P08908 2/20 0.37
ADRA2A P08913 2/20 0.37
ADRA2B P18089 2/20 0.37
ADRA2C P18825 2/20 0.37
HTR1D P28221 1/20 0.37
HTR7 P34969 1/20 0.37
HTR4 Q13639 1/20 0.37
MAOB P27338 2/20 0.37
MAOA P21397 1/20 0.37
CCNC P24863 1/20 0.35
CDK8 P49336 1/20 0.35
CHRM2 P08172 2/20 0.35
CHRM1 P11229 2/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL24337928 0.92 HTR2A (0.44) KMOHTR2AHTR2CHTR2BMAPK1
SCHEMBL29491220 0.92 HTR2A (0.44) KMOHTR2AHTR2CHTR2BMAPK1
SCHEMBL15687474 0.89 MAPK1 (0.44) KMOHTR2AHTR2CMAPK1REN
SCHEMBL3086407 0.88 KMO (0.44) KMOHTR2AHTR2CHTR2BMAPK1
SCHEMBL3780833 0.86 KMO (0.40) KMOHTR2AHTR2CHTR2BMAPK1
SCHEMBL3775268 0.83 MAPK1 (0.41) KMOHTR2AHTR2CHTR2BMAPK1
SCHEMBL3775264 0.83 MAPK1 (0.41) KMOHTR2AHTR2CHTR2BMAPK1
SCHEMBL91363 0.82 KMO (0.58) KMOHTR2AHTR2CHTR2BMAPK1
SCHEMBL3779615 0.81 KMO (0.42) KMOHTR2AHTR2CHTR2BMAPK1
SCHEMBL3777719 0.81 HTR2A (0.44) KMOHTR2AHTR2CHTR2BMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8084485-B2 6-(aminoalkyl)indazoles VITAE PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
US-8084485-B2 6-(aminoalkyl)indazoles VITAE PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
US-8084485-B2 6-(aminoalkyl)indazoles VITAE PHARMACEUTICALS, INC. (US) 2011-12-27 US disclosed
US-20100331287-A1 6-(Aminoalkyl)Indazoles VITAE PHARMACEUTICALS, INC. 2010-12-30 US disclosed
US-20100331287-A1 6-(Aminoalkyl)Indazoles VITAE PHARMACEUTICALS, INC. 2010-12-30 US disclosed
US-20100331287-A1 6-(Aminoalkyl)Indazoles VITAE PHARMACEUTICALS, INC. 2010-12-30 US disclosed
US-7842688-B2 Organic compounds NOVARTIS PHARMA AG (CH) 2010-11-30 US disclosed
US-7790715-B2 Organic compounds NOVARTIS AG (CH) 2010-09-07 US disclosed
US-20090012055-A1 Organic compounds HEROLD PETER 2009-01-08 US disclosed
EP-1961752-A2 Piperidine Compounds Speedel Experimenta AG (CH) 2008-08-27 EP disclosed
WO-2007120523-A2 6-(AMINOALKYL)INDAZOLES VITAE PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed
WO-2007120523-A2 6-(AMINOALKYL)INDAZOLES VITAE PHARMACEUTICALS, INC. (US) 2007-10-25 WO disclosed
US-20070010511-A1 Organic compounds NOVARTIS PHARMA AG (CH) 2007-01-11 US disclosed
EP-1670760-A1 ORGANIC COMPOUNDS Speedel Experimenta AG (CH) 2006-06-21 EP disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed
WO-2005061457-A1 ORGANIC COMPOUNDS SPEEDEL EXPERIMENTA AG (CH) 2005-07-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100331287-A1 6-(Aminoalkyl)Indazoles REN, AGTR1, AGTR2 KMO 3120/4885HTR2A 1966/4885HTR2C 1984/4885
US-20090012055-A1 Organic compounds REN, ACE, ACE2 KMO 2346/4885HTR2A 1006/4885HTR2C 293/4885
US-20070010511-A1 Organic compounds REN, ACE, ACE2 KMO 2346/4885HTR2A 1006/4885HTR2C 293/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.